Details for Patent: 9,464,071

Which drugs does patent 9,464,071 protect, and when does it expire?

Patent 9,464,071 protects BALVERSA and is included in one NDA.

This patent has seventy-four patent family members in thirty-eight countries.

Summary for Patent: 9,464,071

Title:	Pyrazolyl quinoxaline kinase inhibitors
Abstract:	The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
Inventor(s):	Saxty; Gordon (Cambridge, GB), Murray; Christopher William (Cambridge, GB), Berdini; Valerio (Cambridge, GB), Besong; Gilbert Ebai (Bad Duerkheim, DE), Hamlett; Christopher Charles Frederick (Cambridge, GB), Johnson; Christopher Norbert (Cambridge, GB), Woodhead; Steven John (San Diego, CA), Reader; Michael (Bishop's Stortford, GB), Rees; David Charles (Cambridge, GB), Mevellec; Laurence Anne (Louviers, FR), Angibaud; Patrick Rene (Fontaine-Bellenger, FR), Freyne; Eddy Jean Edgard (Rumst, BE), Govaerts; Tom Cornelis Hortense (Betekom, BE), Weerts; Johan Erwin Edmond (Beerse, BE), Perera; Timothy Pietro Suren (Geel, BE), Gilissen; Ronaldus Arnodus Hendrika Joseph (Kasterlee, BE), Wroblowski; Berthold (Vosselaar, BE), Lacrampe; Jean Fernand Armand (Le Mesnil-Esnard, FR), Papanikos; Alexandra (Antwerp, BE), Querolle; Olivier Alexis Georges (Evreux, FR), Pasquier; Elisabeth Therese Jeanne (Le Neubourg, FR), Pilatte; Isabelle Noelle Constance (Louviers, FR), Bonnet; Pascal Ghislain Andre (Berchem, BE), Embrechts; Werner Constant Johan (Beerse, BE), Akkari; Rhalid (Vacquieres, FR), Meerpoel; Lieven (Beerse, BE)
Assignee:	ASTEX THERAPEUTICS LTD (Cambridge, GB)
Application Number:	14/505,020
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,464,071

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-001	Apr 12, 2019		RX	Yes	No						TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-002	Apr 12, 2019		RX	Yes	No						TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-003	Apr 12, 2019		RX	Yes	Yes						TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY

Foreign Priority and PCT Information for Patent: 9,464,071

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	1007286.6	Apr 30, 2010

International Family Members for US Patent 9,464,071

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	3210
Argentina	080982
Australia	2011247047
Australia	2017202512
Brazil	112012027509
Canada	2796204